NADPH Oxidase 5 Is a Pro-Contractile Nox Isoform and a Point of Cross-Talk for Calcium and Redox Signaling—Implications in Vascular Function

Augusto C. Montezano, PhD; Livia De Lucca Camargo, PhD; Patrik Persson, PhD; Francisco J. Rios, PhD; Adam P. Harvey, PhD; Alkaterini Anagnostopoulou, PhD; Roberto Palacios, PhD; Ana Caroline P. Gandara, PhD; Rheure Alves-Lopes, PhD; Karla B. Neves, PhD; Maria Dulak-Lis, PhD; Chet E. Holterman, PhD; Pedro Lagerblad de Oliveira, PhD; Delyth Graham, PhD; Christopher Kennedy, PhD; Aikaterini Anagnostopoulou, PhD; Roberto Palacios, PhD; Ana Caroline P. Gandara, PhD; Rheure Alves-Lopes, PhD; Karla B. Neves, PhD; Maria Dulak-Lis, PhD; Chet E. Holterman, PhD; Pedro Lagerblad de Oliveira, PhD; Delyth Graham, PhD; Christopher Kennedy, PhD; Rhian M. Touyz, MD, PhD

Background—NADPH Oxidase 5 (Nox5) is a calcium-sensitive superoxide-generating Nox. It is present in lower forms and higher mammals, but not in rodents. Nox5 is expressed in vascular cells, but the functional significance remains elusive. Given that contraction is controlled by calcium and reactive oxygen species, both associated with Nox5, we questioned the role of Nox5 in pro-contractile signaling and vascular function.

Methods and Results—Transgenic mice expressing human Nox5 in a vascular smooth muscle cell–specific manner (Nox5 mice) and Rhodnius prolixus, an arthropod model that expresses Nox5 endogenously, were studied. Reactive oxygen species generation was increased systemically and in the vasculature and heart in Nox5 mice. In Nox5-expressing mice, agonist-induced vasoconstriction was exaggerated and endothelium-dependent vasorelaxation was impaired. Vascular structural and mechanical properties were not influenced by Nox5. Vascular contractile responses in Nox5 mice were normalized by N-acetylcysteine and inhibitors of calcium channels, calmodulin, and endoplasmic reticulum ryanodine receptors, but not by GKT137831 (Nox1/4 inhibitor). At the cellular level, vascular changes in Nox5 mice were associated with increased vascular smooth muscle cell [Ca2+]i, increased reactive oxygen species and nitrotyrosine levels, and hyperphosphorylation of pro-contractile signaling molecules MLC20 (myosin light chain 20) and MYPT1 (myosin phosphatase target subunit 1). Blood pressure was similar in wild-type and Nox5 mice. Nox5 did not amplify angiotensin II effects. In R. prolixus, gastrointestinal smooth muscle contraction was blunted by Nox5 silencing, but not by VAS2870 (Nox1/2/4 inhibitor).

Conclusions—Nox5 is a pro-contractile Nox isoform important in redox-sensitive contraction. This involves calcium-calmodulin and endoplasmic reticulum–regulated mechanisms. Our findings define a novel function for vascular Nox5, linking calcium and reactive oxygen species to the pro-contractile molecular machinery in vascular smooth muscle cells. (J Am Heart Assoc. 2018;7: e009388. DOI: 10.1161/JAHA.118.009388.)

Key Words: cell signaling • contraction • vascular biology

Noxs (NADPH oxidases) are a family of enzymes that function primarily to produce reactive oxygen species (ROS) by using molecular oxygen and NADPH as substrates. In phagocytic cells, ROS play a role in host-defense responses, and in nonphagocytic cells, ROS control cell differentiation, proliferation, apoptosis, and senescence.1,2 In the vascular...
Clinical Perspective

What Is New?

- We define a biologically important role for NADPH Oxidase 5 (Nox5) as a regulator of vascular contraction.
- Molecular mechanisms whereby Nox5 regulates contraction involve redox-sensitive processes that influence calcium channels, calcium mobilization, and pro-contractile signaling.
- Nox5 is a point of cross-talk between vascular calcium and redox signaling.
- Vascular Nox5 activation also influences cardiac fibrosis.

What Are the Clinical Implications?

- We identify Nox5 as a key regulator of vascular contraction and cardiac fibrosis.
- Dysregulation of Nox5 may be associated with oxidative stress and amplified calcium signaling, leading to vascular hypercontractility and dysfunction in cardiovascular diseases.
- Modulating Nox5 may have therapeutic potential by targeting both redox and calcium signalling pathways.

Nox5 and Vascular Contraction

Montezano et al

muscle cells (VSMCs), given that increased [Ca^{2+}]_i is the major trigger for vascular contraction. Nox5 is expressed in all vascular cell types, including endothelial cells, VSMCs, and perivascular adventitial fibroblast, and plays a role in angiotensin II (Ang II)- and endothelin-1 (ET-1)-mediated redox signaling. Nox5 expression is increased in human atherosclerotic and aneurysm lesions and in kidneys from diabetic patients. We demonstrated that mice expressing human Nox5 in a podocyte-specific manner exhibit podocyte injury and renal dysfunction, and that human Nox5 expression in mesangial cells causes renal fibrosis, nephropathy, and exacerbated atherosclerosis in diabetic mice. Findings from recent genome wide-association studies of 475 000 individuals identified Nox5 as a candidate blood pressure-associate gene. Together, these data suggest an important (patho)physiological role for Nox5 in the cardiovascular system. However, the exact function of VSMC Nox5 and its biological significance in the vascular system are unknown.

Using a multidisciplinary approach including transgenic Nox5 mice with selective expression of Nox5 in smooth muscle cells, cultured VSMCs from Nox5-expressing mice, and an arthropod model that endogenously expresses Nox5, we identify a novel role for Nox5 as an important pro-contractile NADPH oxidase isoform that regulates vascular contraction and reactivity. We also elucidate some molecular mechanisms underlying Nox5 vascular effects. Nox5 dysregulation may contribute to vascular injury and dysfunction in pathological conditions.

Methods

Mice Expressing Human Nox5 in VSMCs

Generation of Nox5 transgenic mice was approved by the Animal Ethics Committee of the Ottawa Hospital Research Institute, University of Ottawa (Ottawa, Ontario, Canada) and carried out according to the recommendations of the Canadian Council for Animal Care. NOX5β cDNA was PCR amplified from pDONRNox5β plasmid. Purified PCR NOX5β gene-coding region was ligated into the Tet-responsive promoter, Pbi-1. A 3.7-kb TetO/NOX5β fragment was excised and the resulting band gel-purified and provided to the University of Ottawa Core Transgenic Facility for pronuclear injection into fertilized FVB/N oocytes. Subsequent pBi-NOX5β founders on a pure FVB/N background were identified by PCR genotyping. To generate VSMC-specific knockout animals, pBi-Nox5 animals were crossed with the SM22-tTA-FVB/N mouse strain to produce Nox5-/SM22+ and control transgenic mice (SM22+, Nox5+).

In additional studies, adult (20 weeks) WT, SM22+, Nox5+, and Nox5-/SM22+ mice were infused with Ang II (600 ng/kg/day) for 4 weeks by osmotic minipumps. At the end of treatment, tissues were snap-frozen or fixed in formalin for...
analysis. Animal experiments were performed in accord with the United Kingdom Animals Scientific Procedures Act 1986 and ARRIVE (Animal Research: Reporting of In Vivo Experiments) Guidelines and approved by the Home Office under Project Licence No. 7009021.

**Measurement of Blood Pressure**

Systolic blood pressure was assessed by tail-cuff plethysmography.

**Plasma Biochemistry and Plasma Lipid Peroxidation Products**

Plasma biochemistry was determined by an automated analyzer. Plasma lipid peroxidation (malondialdehyde) was determined by quantifying thiobarbituric acid-reactive substances by ELISA.

**Myography to Assess Vascular Function and Structure**

Vascular function was assessed in resistance arteries by wire myography as we previously described. Endothelium-dependent relaxation was assessed in all vessels by concentration-responses to acetylcholine (Ach) where vessels were precontracted with U46619 (thromboxane A2 analogue). Thereafter, endothelium-independent relaxation was assessed by concentration responses to sodium nitroprusside and contractile responses mediated by U46619 evaluated in endothelium-intact arteries. At the end of relaxation and contraction curves, ET-1 induced contraction was assessed. Maximal contraction to KCl was also evaluated before and after addition of pharmacological inhibitors. In some experiments, arteries were preincubated with N-acetylcysteine (ROS scavenger), GKT137831 (Nox1/Nox4 inhibitor), diltiazem (Ca2+ channels blocker), calmidazolium (calmodulin inhibitor), and dantrolene. Dantrolene is considered a potent receptor antagonist of the ryanodine receptor Ca2+ channel in the endoplasmic reticulum (ER), which decreases [Ca2+]i. Studies have demonstrated that dantrolene acts directly on the ryanodine receptor to reduce channel activation by calmodulin and decreases Ca2+ sensitivity of channel activation. Vascular structure and mechanical properties were assessed in resistance arteries prepared as pressurized systems on a pressure myograph as we previously described.

**Cardiac Histology and Fibrosis Staining**

For histochemical analysis, heart sections were stained with picrosirius red (0.1% w/v). Total collagen content (%) was measured in whole tissue under polarized light. To assess cardiomyocyte area, hematoxylin and eosin staining of heart sections was performed. Data were quantified by digital image analysis software (ImageJ; NIH, Bethesda, MD).

**Mouse VSMC Culture**

VSMCs from adult male WT and Nox5−SM22+ mice were studied. Low-passage cells (4–7) were used. VSMCs were stimulated with U46619. In some experiments, cells were preincubated with pharmacological modulators.

**Immunofluorescence**

Nox5 immunofluorescence was performed in human arteries obtained from normotensive and hypertensive subjects and in aortas isolated from WT, SM22+, Nox5−, and Nox5−SM22+ mice.

**Lucigenin-Enhanced Chemiluminescence Assay**

Vascular ROS generation was measured by a luminescence assay with lucigenin as the electron acceptor and NADPH as the substrate.

**Measurement of Nitrotyrosine and H2O2 Levels**

Nitrotyrosine, a measure of peroxynitrite (ONOO−) formation, was assessed in aortic tissue from WT, Nox5−SM22+, SM22+, and Nox5− mice by ELISA. H2O2 was assessed in cardiac tissue from WT, Nox5−SM22+, SM22+, and Nox5− by Amplex Red (Life Technologies).

**Measurement of Superoxide Anion in Cardiac Tissue**

Superoxide levels in hearts from WT, Nox5−SM22+, SM22+, and Nox5− was measured by high-performance liquid chromatography.

**Western Blotting**

Total protein was extracted from mouse VSMCs and from mesenteric arteries from WT, SM22+, Nox5−, and Nox5−SM22+ mice. Antibodies were as follows: MYPT1 (myosin phosphatase target subunit 1; Thr696); p-MLC20 (myosin light chain 20; Thr19/Ser 19); Nox1; Nox2; Nox4; and Nox5. Antibodies to β-actin or GAPDH were used as housekeeping controls. After incubation with secondary fluorescence-coupled antibodies (LI-COR Biosciences, Lincoln, NE), signals were visualized by an infrared laser scanner.

**Real-Time PCR**

Total RNA was isolated from cardiac samples from WT, SM22+, Nox5−, and Nox5−SM22+ mice. Real-time PCR was
performed with specific mouse primers for Nox2 and Nox4. Data are shown as the fold change in expression of the target gene relative to the internal control gene GAPDH.\textsuperscript{36}

**Measurement of Intracellular Free Ca\textsuperscript{2+} Concentration ([Ca\textsuperscript{2+}]i) in VSMCs**

[Ca\textsuperscript{2+}]i was measured in VSMCs from WT and Nox5\textsuperscript{+}/SM22\textsuperscript{+} mice using the fluorescent Ca\textsuperscript{2+} indicator, Cal-520 ace-toxymethyl ester (Cal-520/AM).

**Nox5-Expressing Arthropod Model: Rhodnius prolixus**

*Rhodnius prolixus* was studied as an arthropod model that expresses Nox5 endogenously. Insects were fed with rabbit blood as a stimulus for gut contraction.

**siRNA Downregulation of Nox5 in *R*. prolixus**

A 457-bp fragment from the Nox5 gene was amplified from reverse-transcribed RNAs extracted from *R. prolixus* midguts using the primer pairs NOX5Ds1. For gene-silencing experiments, adult *R. prolixus* were injected with dsRNA. Six days after dsRNA injection, insects were fed.

**RNA Extraction, PCR, and qPCR: *R*. prolixus**

Total RNA was extracted from anterior midguts using TRIzol and cDNA was synthesized. cDNA from anterior midguts were PCR-amplified using the PCR master mix, and the same primers were used for qPCR. The *R. prolixus* EF-1 S rRNA gene was used as an endogenous control.

**VAS2870 Injection in *R*. prolixus**

In some experiments, *R. prolixus* were injected with VAS2870 to inhibit Nox 1, 2, and 4 six days before feeding.

**Images and Video Acquisition of Gut Contractions in Nox5-Silenced *R*. prolixus**

Nox5-siRNA–injected and VAS2870-treated insects were studied 7 days after a blood meal. Peristaltic contractions of the anterior midguts were recorded for 2 minutes by video fluorescence microscopy.

**Statistical Analysis**

Data are presented as mean±SEM. Statistical comparisons were made with 1-way ANOVA followed by Dunnet’s post-hoc or 2-tailed Student t test, when appropriate. \(P<0.05\) was considered statistically significant.

**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request. Additional methods can be found in Data S1.

**Results**

**Phenotypic Characterization of Nox5 Mice**

The mouse genome lacks Nox5 and, accordingly, to study the biological in vivo significance of vascular Nox5, we created humanized transgenic mice that selectively express Nox5 in smooth muscle cells (Nox5\textsuperscript{+}/SM22\textsuperscript{+}). Nox5 expression, assessed by immunofluorescence, was observed only in Nox5\textsuperscript{+}/SM22\textsuperscript{+} mice and not in any of the control groups (WT, SM22\textsuperscript{+}, and Nox5\textsuperscript{−}), confirming the selective Nox5 expression in the experimental transgenic mice (Figure 1A). Systemic oxidative stress, measured by plasma levels of lipid peroxidation (plasma malondialdehyde levels), was already increased in basal conditions in Nox5\textsuperscript{+}/SM22\textsuperscript{+} mice (Figure 1B) and was not further enhanced by Ang II infusion.

Ang II infusion for 4 weeks increased systolic blood pressure in all groups, without differences between control and Nox5\textsuperscript{−}/SM22\textsuperscript{−} mice (Figure 1C). Body weight and plasma biochemistry were not significantly different between groups, although Ang II increased plasma phosphate levels in WT, SM22\textsuperscript{−}, and Nox5\textsuperscript{−}/SM22\textsuperscript{−} mice (Table S1). Causes for the hyperphosphatemia are unclear.

Cardiac superoxide anion (Figure 2A), H\textsubscript{2}O\textsubscript{2} (Figure S1A), and thiobarbituric acid-reactive substances levels (Figure S1B) were increased in Nox5\textsuperscript{−}/SM22\textsuperscript{−}. Ang II increased superoxide, H\textsubscript{2}O\textsubscript{2}, and TBARS levels only in wild-type (WT) mice. Heart weight was only increased in control mice treated with Ang II (Figure 2B). Collagen deposition was increased in hearts from Nox5\textsuperscript{−}/SM22\textsuperscript{−} mice (Figure 2C and 2D). Ang II increased collagen deposition in cardiac tissue from WT, mice. Histological analysis demonstrated that cardiomyocyte area was increased in cardiac tissue from Nox5\textsuperscript{−}/SM22\textsuperscript{−} mice, to a similar extent to that in Ang II–infused WT mice (Figure 2E).

**Vascular Function in Nox5 Mice**

Concentration-response curves to the thromboxane A2 analogue, U46619 (contraction), Ach (endothelial-dependent relaxation), and sodium nitroprusside (endothelial-independent relaxation) were performed in all groups to assess whether expression of Nox5 in VSMCs influences vascular function. Vascular contraction induced by U46619 was
increased in Nox5+/SM22+ mice compared with all control groups (WT, Nox5+, and SM22+; Figure 3A). In Ang II–infused mice, contractile responses were significantly enhanced in WT and Nox5+/SM22+ mice (Figure 3B). There were no significant differences in contractile responses between the control groups (WT, Nox5+, and SM22+) in basal conditions or in mice treated with Ang II (Figure S2). The importance of ROS was observed by exposure of isolated arteries to N-acetylcysteine, an ROS scavenger, that significantly attenuated U46619-induced contractile responses in Nox5+/SM22+ mice, with only a modest effect in WT mice (Figure 3C). GKT137831, a Nox1/4 inhibitor, did not significantly alter contractile responses in WT or Nox5+/SM22+ mice (Figure 3D). In previous studies, we showed that activation of the Ca2+/calmodulin pathway is important for Nox5-dependent effects in VSMCs. Here, we found that contractile responses in WT and Nox5+/SM22+ groups were significantly reduced in vessels exposed to the calmodulin inhibitor, calmidazolium (Figure 3E). Dantrolene, which inhibits ryanodine receptors and prevents Ca2+ release from the ER, attenuated contraction in Nox5+/SM22+ mice without effect in WT mice (Figure 3F).

Increased vascular contraction in Nox5+/SM22+ mice was not agonist specific, but appears to be a generalized phenomenon, given that maximal responses to KCl and ET-1 were also exaggerated in Nox5-expressing mice compared with control groups (Figure 4). Contractile responses to KCl and ET-1 were significantly reduced in Nox5+/SM22+ vessels exposed to diltiazem, calmidazolium, and N-acetylcysteine (Figure 4B through 4F). GKT137831 did not reduce KCl- or ET-1–induced contraction (Figure 4C through 4E). Associated with exaggerated contraction, Ach-induced vasorelaxation (endothelium-dependent relaxation) was significantly reduced in Nox5+/SM22+ mice (Figure 5A). In Ang II–infused WT and Nox5+/SM22+ mice, Ach-mediated vasorelaxation was significantly reduced, with maximal dilatory responses of only 10% to 20% (Figure 5B). Ach-mediated responses were not different between respective WT, Nox5+, and SM22+ control groups (Figure 5C). SNP-induced vasorelaxation was similar in all groups and was unaffected by Nox5 expression or by Ang II infusion (Figure S3A through S3C).

Vascular Structure and Mechanical Properties in Nox5+/SM22+ Mice

Small mesenteric arteries were also studied as pressurized systems to assess vascular structure and mechanical properties. In basal conditions, there were no structural differences between any groups as assessed by measuring cross-sectional area (Figure 6A) and wall-to-lumen ratio (Figure S4A). Cross-sectional area was increased in all Ang II–infused groups (Figure 6B and 6C), with modest effect in Nox5-expressing mice compared with WT mice. In Ang II–infused mice, wall-to-lumen ratio was increased in Nox5+/SM22+ mice compared with WT and vehicle-treated Nox5+/SM22+ counterparts (Figure S4C and S4D). Vascular stiffness and distensibility, assessed by stress/strain relationships, were not significantly different between any groups (Figure S5).
Molecular Mechanisms Associated With Vascular Dysfunction in Nox5 Mice

Nox5 produces $O_2^-$ that interacts with nitric oxide to form ONOO$, which binds to tyrosine residues of proteins to form nitrotyrosine. As shown in Figure 7A, vascular nitrotyrosine levels were significantly increased in vessels from Nox5$^+$SM22$^+$ mice. To better evaluate molecular mechanisms contributing to hypercontractility in Nox5$^+$SM22$^+$ mice, VSMCs cultured from mesenteric arteries from WT and Nox5$^+$SM22$^+$ mice were studied. Nox5$^+$SM22$^+$ VSMCs exhibited increased NADPH-induced ROS production (Figure 7B), effects that were attenuated by verapamil, calmidazolium, and dantrolene (Figure 7C). Stimulation of WT and Nox5$^+$/SM22$^+$ VSMCs with the vasoconstrictor, U46619, induced a rapid increase in ROS production (within 5–15 minutes; Figure 7D and 7E). U46619-induced ROS production was inhibited in Nox5$^+$SM22$^+$ VSMCs pretreated with verapamil and dantrolene (Figure 7F).

Key molecular processes involved in vascular contraction are increased $[Ca^{2+}]$, and phosphorylation of MYPT1 and MLC20,
Figure 3. Vascular contraction is increased in Nox5+/SM22+ mice. A, Vascular contractility to U46619 assessed by wire myography in mesenteric arteries from WT (open circle), SM22+ (open triangle), Nox5+ (open rhombus) and Nox5+/SM22+ (open square). B, Vascular contractility to U46619 in mesenteric arteries from WT (open circle), WT+Ang II (closed circle), Nox5+/SM22+ (open square), and Nox5+/SM22+/Ang II (closed square) mice. C, Vascular contractility to U46619 in mesenteric arteries from WT (open circle) and Nox5+/SM22+ (open square) mice in the presence of N-acetylcysteine (NAC; 10 μmol/L) (WT, closed circle; Nox5+/SM22+, closed square). Vessels were pre-incubated with NAC for 1 hour. D, Vascular contractility to U46619 in arteries from WT (open circle) and Nox5+/SM22+ (open square) mice in the presence of GKT137831 (10 μmol/L; WT, closed circle; Nox5+/SM22+, closed square). Vessels were preincubated with GKT137831 for 1 hour. E, Vascular contractility to U46619 in mesenteric arteries from WT (open circle) and Nox5+/SM22+ (open square) mice in the presence of calmidazolium (Calmid; 1 μmol/L; WT, closed circle; Nox5+/SM22+, closed square). Vessels were preincubated with calmidazolium for 1 hour. F, Vascular contractility to U46619 in arteries from WT (open circle) and Nox5+/SM22+ (open square) mice in the presence of dantrolene (Dant; 10 μmol/L; WT, closed circle; Nox5+/SM22+, closed square). Vessels were preincubated with dantrolene for 1 hour. Results are mean±SEM of 3 to 8 mice/group. *P<0.05 vs WT; **P<0.05 vs untreated WT or Nox5+/SM22+ (open symbols). Ang II indicates angiotensin II; Nox5, NADPH Oxidase 5; WT, wild-type.
which trigger actin-myosin cross-bridge formation. Ionomycin-stimulated Ca\textsuperscript{2+} influx was significantly greater in Nox5\textsuperscript{5+}/SM22\textsuperscript{+} VSMCs compared with WT cells (Figure 8A). These processes were associated with increased phosphorylation of the inhibitory regulatory subunit of MLCP (myosin light chain phosphatase), MYPT1 (Figure 8B through 8D). Phosphorylation of MLC20 (Thr 18/Ser 19) was greater in Nox5\textsuperscript{5+}/SM22\textsuperscript{+} VSMCs compared with WT controls (Figure 8C and 8D).

Figure 4. Maximum contraction to KCl and ET-1–induced contraction are increased in arteries from Nox5\textsuperscript{5+}/SM22\textsuperscript{+} mice. A, Vascular contraction to a single concentration of KCl (62.5 mmol/L) in mesenteric arteries from WT, Nox5\textsuperscript{5+}/SM22\textsuperscript{+}, SM22\textsuperscript{+}, and Nox5\textsuperscript{5+} mice, before and after treatment with Ang II. B, Vascular contraction to KCl in mesenteric arteries from WT and Nox5\textsuperscript{5+}/SM22\textsuperscript{+} mice, before and after preincubation (1 hour) with diltiazem (10 μmol/L) or calmidazolium (10 μmol/L). C, Vascular contraction to KCl in mesenteric arteries from WT and Nox5\textsuperscript{5+}/SM22\textsuperscript{+} mice, before and after preincubation (1 hour) with NAC (10 μmol/L) or GKT137831 (10 μmol/L). D, Vascular contraction to a single concentration of ET-1 (0.1 mmol/L) in mesenteric arteries from WT and Nox5\textsuperscript{5+}/SM22\textsuperscript{+} mice. Vascular contraction to ET-1 in mesenteric arteries from WT and Nox5\textsuperscript{5+}/SM22\textsuperscript{+} mice, before and after preincubation (1 hour) with NAC (10 μmol/L) or GKT137831 (10 μmol/L; E) or calmidazolium (10 μmol/L; F). Results are mean±SEM of 3 to 8 mice/group. *P<0.05 vs WT; **P<0.05 vs untreated mice. Ang II indicates angiotensin II; ET-1, endothelin-1; NAC, N-acetylcysteine; Nox5, NADPH Oxidase 5; WT, wild-type.
Differential Expression of Vascular Nox Isoforms in Nox5+SM22+ Mice

To evaluate whether human Nox5 influences expression of endogenous Nox isoforms in vessels from Nox5+SM22+ mice, we measured protein content of Nox1, Nox2, and Nox4 in vascular tissue from WT and Nox5+SM22+ mice. As shown in Figure S6, expression of Nox2 and Nox4 was not different between WT and Nox5+SM22+ groups. However, expression of Nox1 was increased in Nox5+SM22+ mice compared with WT counterparts. In heart tissue, we did not observe any differences in mRNA levels of Nox2 (Figure S7A) and Nox4 (Figure S7B), whereas mRNA levels of Nox1 were undetected.

Decreased Gut Contraction in Nox5-Silenced R. prolixus

To further examine the role of Nox5 in an intact system that endogenously expresses functionally active Nox5, we studied R. prolixus. As shown in Figure S8A, exposure of WT R. prolixus to a feeding stimulus induced a significant increase in Nox5 expression. Silencing of Nox5 with dsRNA resulted in a significant reduction in frequency of midgut contraction (peristalsis) following feeding, suggesting an important role for Nox5 in gut muscle contraction (Figure S8B). VAS2870, a Nox1/4 inhibitor, at low (0.02 mmol/L) and high (0.1 mmol/L) concentrations, had no effect on feeding-stimulated peristaltic contraction (Figure S8C).

Discussion

Since its discovery, the function of Nox5 and the significance of its absolute dependency on intracellular Ca2+ for its activation have been elusive. Here, we provide new insights into the pathophysiological role of Nox5, identifying it as a novel regulator of smooth muscle contraction important in vascular function. Major findings from our study demonstrate that: (1) transgenic mice expressing human Nox5 in VSMCs exhibit systemic and vascular oxidative stress and vascular hypercontractility, responses that are normalized by inhibitors of Ca2+ channels, calmodulin, and ER ryanodine receptors;
vascular expression of Nox5 is associated with cardiac oxidative stress and fibrosis; and (3) Nox5 does not influence Ang II pressor responses. These data define Nox5 as a pro-contractile Nox isoform that regulates vascular contraction through molecular processes involving ROS, Ca\(^{2+}\), calmodulin, and the ER. In support of our findings, we demonstrated that muscle contraction in an invertebrate model that expresses Nox5 endogenously is attenuated when Nox5 is silenced, but not when Nox1 and Nox4 are inhibited. Together, our studies identify a novel function for Ca\(^{2+}\)-sensitive Nox5 in redox regulation of smooth muscle contraction, processes that may have significant implications in vascular (patho)physiology.

Nox5 was originally identified in testis, ovaries, spleen, and immature lymphocytes and is heavily expressed in various cancers. More recently, Nox5 has been demonstrated in the vascular system. In bovine aortic endothelial cells, Nox5 is required for stromal cell–derived factor-1α and MAPK (mitogen-activated protein kinase) signaling, which regulate endothelial migration and angiogenesis. In human endothelial cells, Ang II– and ET-1–induced redox signaling and MAPK activation are Nox5 dependent. In adenovirus-mediated Nox5 overexpression in endothelial cells, phosphorylation of p38 MAPK, JAK2 (Janus kinase 2), JNK (c-Jun N-terminal kinase), and ERK1/2 (extracellular signal-regulated kinases 1 and 2) was increased, whereas in VSMCs, Nox5 only increased ERK1/2 phosphorylation. To investigate the pathophysiological significance of vascular smooth muscle Nox5 in vivo, we generated mice expressing human Nox5 exclusively in smooth muscle cells.
These mice exhibited significant oxidative stress, both systemically and in the vasculature and heart, indicating the functional activation of ROS-generating Nox5 in our model. Although these mice had normal blood pressure, they exhibited significant changes in vascular function as well as some evidence of cardiac changes, particularly fibrosis and cardiomyocyte hypertrophy, suggesting that Nox5-induced ROS generation in the vasculature impacts cardiac cells, possibly through redox-sensitive signaling pathways. The most marked phenotype in the Nox5 mice was vascular...
hypercontractility, which was not exacerbated by Ang II. Potential mechanisms associated with Nox5-induced vascular changes involve ROS, Ca²⁺, and calmodulin, because vascular hyper-reactivity was normalized by N-acetylcysteine, Ca²⁺ channel blockers, and calmidazolium. These findings are in line with the fact that Nox5-derived ROS production is dependent on [Ca²⁺]i and calmodulin. In our study, Ca²⁺ mobilization may be important because dantrolene, which blocks ryanodine receptor, reduced contraction only in Nox5 mice. Previous studies in coronary arterial myocytes and pulmonary arterial smooth muscle cells demonstrated that ryanodine receptor/Ca²⁺ regulation involves ER-associated Nox (2 and 4)-derived ROS. Our findings are supportive of this association, although the exact role of Nox5 in ER function warrants further investigation.

Nox isoforms may regulate one another, either through redox-dependent processes that influence transcription factors and gene expression or directly through protein-protein interactions. In our study, Nox5 did not influence Nox2 or Nox4 expression, in the vasculature or heart, but it was...
associated with an increase in vascular Nox1 content. Reasons for this remain unclear. However, Nox1 upregulation did not seem to significantly influence vascular hypercontractility in Nox5 mice because GKT137831 did not inhibit exaggerated contractile responses in Nox5-expressing mice.

Molecular processes underlying Nox5-induced vascular dysfunction were further interrogated in VSMCs cultured from WT and Nox5 mice. In Nox5-expressing cells, oxidative stress, [Ca^{2+}], and pro-contractile signaling pathways were increased. In particular, phosphorylation of MYPT1 at Thr-696 and phosphorylation of MLC20 at Thr18/Ser19 were increased in VSMCs from Nox5 mice. Phosphorylation of MYPT1 causes inhibition of myosin phosphatase, which leads to increased Ca^{2+} sensitization and increased force of vascular smooth muscle contraction. Hence, the increased phosphorylation of MYPT1 and MLC20 in the Nox5-expressing mice may be indicative of increased pro-contractile signaling, which is in line with our other vascular findings.

In addition to increased contraction, Nox5-expressing mice exhibited impaired endothelium-dependent vasorelaxation, processes that were associated with reduced phosphorylation of endothelial nitric oxide synthase and increased vascular ONOO\(^{-}\) content. Given that Nox5 was expressed exclusively in vascular smooth muscle in our mouse model, it is unlikely that the endothelial changes are directly attributed to Nox5. However, there may be important cross-talk between the endothelium and vascular media through Nox5-derived ROS, where vascular oxidative stress in Nox5 mice may promote endothelial nitric oxide synthase uncoupling, decreased endothelial nitric oxide synthase activation with reduced nitric oxide generation, increased superoxide production, and consequent ONOO\(^{-}\) formation, processes that cause endothelial dysfunction.

In Ang II-infused WT mice, contractile responses were increased and endothelium-dependent vasorelaxation was impaired. These effects were not further aggravated by Nox5. Reasons for this are unclear, but may relate, at least in part, to the fact that in Nox5 mice vessels are already hypercontractile with endothelial dysfunction in the basal state before Ang II treatment and that further responses may be blunted.

Despite the critical role of Nox5 in the regulation of vascular function, it seemed to be less important in processes that control vascular structure and mechanics, given that vascular wall thickness, stiffness, and distensibility were not influenced by Nox5 in basal conditions, despite increased oxidative stress. When challenged with Ang II, arteries from WT mice exhibited significant remodeling as evidenced by an increase in cross-sectional area. In Ang II-infused Nox5 mice, remodeling was less marked than WT counterparts. Preservation of vascular structure and mechanical integrity, and modest remodeling induced by Ang II, may explain, at least in part, why Nox5 did not significantly influence blood pressure in basal or Ang II-stimulated conditions.

During evolution, for unknown reasons, the Nox5 gene was lost in rodents, but is present and functionally active in some invertebrates and in higher mammals. Arthropods possess Nox5, an ortholog of human Nox5, besides dual oxidase, and some of them also possess Nox4-art, a gene related to Nox4. As such, we further examined the relationship between Nox5 and contraction by studying R. prolixus where midgut contraction is easily studied by videomicroscopy. Feeding induced a significant increase in Nox5 expression in R. prolixus, with associated increase in midgut contraction. However, in Nox5-silenced R. prolixus, feeding-stimulated contractile responses were markedly blunted, highlighting the importance of Nox5 in the regulation of muscle contraction. This was confirmed in our studies with VAS2870, a NOX1/4 inhibitor that had no effect on feeding-stimulated peristaltic contractions. The biological importance of Nox5 in smooth muscle contraction was also shown in Drosophila melanogaster, where depletion of Nox5 (dNox) in the musculature was studied using RNA interference approaches. Drosophila exhibited retention of mature eggs, impaired ovarian muscle contractions, and sterility attributed to altered agonist-induced calcium flux and decreased muscle contraction. The muscles that control Rhodnius gut and Drosophila ovarian muscles are typical of smooth muscle and derive from mesoderm, similar to that in mammals, and hence biological processes controlling contraction may be similar between species. Together these findings strongly support the notion that Nox5 is a pro-contractile NADPH oxidase isoform, an ancestral role that is conserved during animal evolution.

In conclusion, using a multidisciplinary approach, including Nox5 transgenic mice, cultured VSMCs from Nox5 mice, and Nox5-expressing arthropod models, we define an important role for Nox5 in the regulation of smooth muscle contraction and vascular function. Nox5 may be a key nexus linking Ca^{2+} and ROS to the pro-contractile molecular machinery in VSMCs. Upregulation of the Ca^{2+}-regulated Nox5-ROS-Ca^{2+} pathway may be especially important in cardiovascular diseases associated with vascular hypercontractility, such as coronary artery disease, vasospastic conditions, hypertension, and cerebral vasospasm.

Acknowledgments
We thank Wendy Beattie, Laura Haddow, Jacqueline Thomson, and Carol Jenkins (University of Glasgow) for technical assistance.

Sources of Funding
This work was supported by grants from the British Heart Foundation (BHF) (RG/13/7/30099; RE/13/5/30177). Montezano was supported through a Walton Fellowship in Cardiovascular Medicine.
Disclosures
None.

References


